Location of Repository

Substandard medicines in resource-poor settings: A problem that can no longer be ignored

By J M Caudron, N Ford, M Henkens, C Macé, R Kiddle-Monroe and J Pinel

Abstract

The circulation of substandard medicines in the developing world is a serious clinical and public health concern. Problems include under or over concentration of ingredients, contamination, poor quality ingredients, poor stability and inadequate packaging. There are multiple causes. Drugs manufactured for export are not regulated to the same standard as those for domestic use, while regulatory agencies in the less-developed world are poorly equipped to assess and address the problem. A number of recent initiatives have been established to address the problem, most notably the WHO pre-qualification programme. However, much more action is required. Donors should encourage their partners to include more explicit quality requirements in their tender mechanisms, while purchasers should insist that producers and distributors supply drugs that comply with international quality standards. Governments in rich countries should not tolerate the export of substandard pharmaceutical products to poor countries, while developing country governments should improve their ability to detect substandard medicines

Year: 2008
DOI identifier: 10.1111/j.1365-3156.2008.02106.x
OAI identifier: oai:fieldresearch.msf.org:10144/37334
Provided by: MSF Field Research
Journal:

Suggested articles

Preview

Citations

  1. (2005). AIDS Drugs Hit Roadblock in Africa – Dispute Over Generics Stalls Treatment Efforts.
  2. (2005). Comparative behavioural study in dissolution of various Glibenclamide generic tablets with princeps drugs.
  3. (2003). Directive
  4. (2006). Guidance for Industry Testing of Glycerin for Diethylene Glycol. US Food and Drug Administration,
  5. (1995). Inadvertent supply of substandard drugs.
  6. (2008). J.-M. Caudron et al. Substandard medicines in poor countries 1070 ª
  7. (2006). L’arte´sunate: quelles pre´cautions fautil prendre pour la conservation des comprime´s?
  8. (2005). Murder by medicine.
  9. (2002). PagesM,Videau JY&Yameogo O
  10. (2007). Quality control of active ingredients
  11. (2006). Review of Quality Assurance (QA) Mechanisms for Medicines and Medical Supplies in Humanitarian Aid. European Commission Humanitarian Aid – Concept Paper,
  12. (1989). Rifampicin raw material characteristics and their effect on bioavailability.
  13. (2002). Substandard and counterfeit drugs in developing countries.
  14. (1997). Supplies for humanitarian aid and development countries: the quality of essential multisources drugs.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.